0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessThere was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD.
Jonathan Y. M. Lai, David R. Riley, Matthew Anson, Alex E. Henney, Daniel J. Cuthbertson, Gema Hernadez, Philip Austin, Professor Gregory Lip, Sizheng Steven Zhao, Timothy L. Jackson, Katarzyna Nabrdalik, Uazman Alam (2024). Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis. , 15(4), DOI: https://doi.org/10.1007/s13300-024-01544-3.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2024
Authors
12
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1007/s13300-024-01544-3
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
